RVO
HomeMarketplace

Project cooperationUpdated on 1 September 2025

Neo-adjuvant oncolytic immune activator

Wenliang Dong

CEO at ORCA Therapeutics BV

Amsterdam, Netherlands

About

Background: Current immune checkpoint inhibitors (ICIs) fail in 80% of cancer patients, primarily due to "cold" tumor microenvironments that lack immune infiltration. ORCA-010 has demonstrated the unique ability to convert cold tumors to hot in 100% of treated patients through enhanced oncolytic viral activity and sustained immune activation.

Collaboration Opportunity: We seek strategic partnerships with pharmaceutical companies developing checkpoint inhibitors to explore combination therapy synergies. ORCA-010's proven ability to induce durable immune activation creates an ideal foundation for rational combination strategies with PD-1/PD-L1, CTLA-4, or next-generation checkpoint inhibitors.

Similar opportunities